9II Stock Overview
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Biovica International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.12 |
| 52 Week High | kr0.84 |
| 52 Week Low | kr0.11 |
| Beta | 1.21 |
| 1 Month Change | -41.38% |
| 3 Month Change | -41.38% |
| 1 Year Change | -80.27% |
| 3 Year Change | -96.99% |
| 5 Year Change | n/a |
| Change since IPO | -97.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9II | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -28.6% | 0.7% | 2.0% |
| 1Y | -80.3% | -24.4% | 2.0% |
Return vs Industry: 9II underperformed the German Biotechs industry which returned -22.8% over the past year.
Return vs Market: 9II underperformed the German Market which returned 1.3% over the past year.
Price Volatility
| 9II volatility | |
|---|---|
| 9II Average Weekly Movement | 14.0% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 9II's share price has been volatile over the past 3 months.
Volatility Over Time: 9II's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 37 | Anders Rylander | www.biovica.com |
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a biomarker assay that measures thymidine kinase activity, which reflects tumor cell proliferation.
Biovica International AB (publ) Fundamentals Summary
| 9II fundamental statistics | |
|---|---|
| Market cap | €12.26m |
| Earnings (TTM) | -€10.51m |
| Revenue (TTM) | €595.32k |
20.6x
P/S Ratio-1.2x
P/E RatioIs 9II overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9II income statement (TTM) | |
|---|---|
| Revenue | kr6.97m |
| Cost of Revenue | -kr483.00k |
| Gross Profit | kr7.45m |
| Other Expenses | kr130.44m |
| Earnings | -kr122.99m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
Jun 18, 2024
| Earnings per share (EPS) | -1.46 |
| Gross Margin | 106.93% |
| Net Profit Margin | -1,765.84% |
| Debt/Equity Ratio | 0% |
How did 9II perform over the long term?
See historical performance and comparison